- Patient/Guest
- Phlebotomist
- Updates
| Dual Screen NT | - |
|---|
|
Assess fetal aneuploidy with NT |
||
 |
Synonym | See updates |
 |
Test Code | CDBIOPR0042 |
 |
Test Type | Biochemistry |
 |
Pre-Test Condition | See updates |
 |
Report Availability | 3 D(s) |
 |
# Test(s) | Multiple |
| Test details | Sample Report |
|---|---|
| Dual Screen NT |
|
|
Synonym | See updates | |
|
Test Code | CDBIOPR0042 | |
 |
Test Category | Fetal aneuploidy | |
|
Pre-Test Condition | See updates | |
 |
Medical History | See updates | |
|
Report Availability | 3 D(s) | |
 |
Specimen/Sample | Serum; 2 mL; SST | |
 |
Stability @21-26 deg. C | 6 Hr(s) | |
 |
Stability @ 2-8 deg. C | 7 D(s) | |
 |
Stability @ Frozen | 1 M(s) | |
|
# Test(s) | Multiple | |
 |
Processing Method | Immunoassay | |
| **Dual Screen and NT****FDA Status**: FDA-approved for prenatal screening.**Other Names**: First Trimester Dual Marker Test, Combined Screening with NT.**Historical Breakthrough**: Developed in the 1990s for early prenatal screening, advancing obstetrics.**Key Purpose and Impact**: Measures PAPP-A, free β-hCG, and nuchal translucency (NT) to assess Down syndrome risk.**Preparation and Patient History**: Blood and ultrasound; report pregnancy history or family history.**Consent Requirement**: Standard consent with prenatal counseling.**Clinical Value**: Sensitivity ~95%; specificity ~95%; detects abnormalities in ~90% of cases; guides further testing.**References Cited**: Testing.com Prenatal Tests 2023; Labcorp Dual Screen 2025; UpToDate Prenatal Screening 2025 |